Search | Clinical Trials Finder

Conditions: Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions: SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS); Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Drug Addiction
Interventions: Within-subjects (MDMA), Within-subjects (oxytocin), Within-subjects (placebo); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Plaque-type Psoriasis
Interventions: CJM112, Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Anniston, Alabama • Anaheim, California • Encino, California + 14 more

Conditions: Bioequivalence Study
Interventions: Clocortolone Pivalate; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Leiomyoma
Interventions: Brachial artery catheter, Acetylcholine, Nitroprusside, Norepinephrine, Nitroprusside and phenylephrine; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Opioid Use Disorder, Opioid Misuse, Chronic Pain
Interventions: TCM, TCM plus COPES; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Little Rock, Arkansas • Aurora, Colorado • West Haven, Connecticut

Conditions: Treatment Resistant Depression
Interventions: Moderate Intensity Aerobic Exercise, Wait-list; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Healthy Volunteers
Interventions: Deflazacort and rifampin, Deflazacort and Clarithromycin; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Abuse Potential
Interventions: Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg, pregabalin 450 mg with oxycodone 20 mg, oxycodone 20 mg, Placebo; Drug
Lead sponsor: Viatris Specialty LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Chronic Angle-closure Glaucoma
Interventions: Rho-Kinase Inhibitor; Drug
Lead sponsor: New York Glaucoma Research Institute; Other
Eligibility: 50 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis Pain, Chronic Low Back Pain, Pain Due to Interstitial Cystitis
Interventions: placebo, tanezumab; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Behavior, Anxiety
Interventions: Placebo then intranasal oxytocin, Intranasal oxytocin then placebo; Drug
Lead sponsor: MacDonald, Kai, M.D.; Individual
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Obesity
Interventions: Behavioral Treatment, Placebo, Phentermine 15 MG; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Advanced Solid Tumor
Interventions: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 6
States / cities: Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more

Conditions: Healthy
Interventions: Ultravate® 0.05% ointment, single exposure; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: San Diego, California

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: methylphenidate, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1986 – 1994
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions: Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise; Drug · Procedure · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 26
States / cities: Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more

Conditions: Breast Surgery
Interventions: Pecs-2 block (single injection), Paravertebral block (single injection); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Sickle Cell Disease
Interventions: Voxelotor Oral Tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 30 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: St Louis, Missouri • The Bronx, New York

Conditions: Alcohol Use Disorder
Interventions: DCR-AUD, Placebo; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Sleep Disordered Breathing, Able Bodied
Interventions: Acetazolamide + supplemental oxygen + PAP therapy, Zolpidem + PAP therapy, Buspirone + PAP therapy; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 570, AMG 570 Matching Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Search by objective public record fields.

Peripheral Immune System in Individuals With Schizophrenia

Effects of MDMA on Social and Emotional Processing

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream

Vascular Function and Uterine Fibroids

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Pain Care at Home to Amplify Function (Pain CHAMP)

Exercise in Treatment Resistant Depression (TRD): A Feasibility Study

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting

Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

Further Studies of Attention Deficit Disorder - Residual Type (RT)

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

Pectoralis Block vs Paravertebral Nerve Blocks for Breast Surgery

Voxelotor Brain Oxygenation and Neurocognitive Study

Phase 1b Study of DCR-AUD in Healthy Volunteers

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

Single Ascending Dose Study of AMG 570 in Healthy Subjects

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study